Buy Epithra : Epirubicin 100 Mg Injection Online

Description

Description: Epithra, manufactured by Glenmark (Onkos) Pharmaceuticals Ltd., is a sterile injectable formulation containing 100 mg of the active substance Epirubicin. Epithra belongs to the class of anthracycline antibiotics and is widely used in the treatment of various types of cancer, including breast cancer, ovarian cancer, and soft tissue sarcomas. As a potent cytotoxic agent, Epithra is administered intravenously under medical supervision to target and destroy cancer cells, ultimately inhibiting tumor growth and improving patient outcomes.

Active Substance: The active substance in Epithra is Epirubicin, a semi-synthetic derivative of doxorubicin with potent antineoplastic properties. Epirubicin exerts its pharmacological effects by intercalating with DNA, inhibiting topoisomerase II enzyme activity, and generating free radicals that induce DNA damage and apoptosis (programmed cell death) in cancer cells. This mechanism of action makes Epirubicin an effective chemotherapeutic agent for the treatment of various malignancies.

Indications: Epithra is indicated for the treatment of:

• Breast Cancer: Epithra is used as adjuvant therapy or palliative treatment for both early-stage and advanced breast cancer, either as monotherapy or in combination with other chemotherapeutic agents.
• Ovarian Cancer: Epithra may be used as part of first-line or salvage therapy for epithelial ovarian cancer, particularly in cases where standard treatments have failed.
• Soft Tissue Sarcomas: Epithra is utilized in the management of advanced soft tissue sarcomas, including liposarcoma, leiomyosarcoma, and malignant fibrous histiocytoma.

Mechanism of Action: Epirubicin exerts its anticancer effects through multiple mechanisms, including:

• DNA Intercalation: Epirubicin intercalates with DNA strands, disrupting DNA replication and transcription processes in cancer cells.
• Topoisomerase II Inhibition: Epirubicin inhibits topoisomerase II enzyme activity, leading to DNA strand breaks and inhibition of DNA repair mechanisms.
• Free Radical Formation: Epirubicin generates reactive oxygen species (ROS) and free radicals, causing oxidative damage to cellular components and triggering apoptosis in cancer cells.

Benefits:

• Effective Cancer Treatment: Epithra offers a potent and effective treatment option for patients with breast cancer, ovarian cancer, and soft tissue sarcomas, helping to reduce tumor burden and improve clinical outcomes.
• Flexible Administration: Epithra can be administered intravenously in various settings, including hospitals, outpatient clinics, and infusion centers, allowing for flexible treatment scheduling and patient convenience.
• Adjuvant and Palliative Therapy: Epithra can be used as adjuvant therapy to prevent cancer recurrence after surgery or as palliative treatment to relieve symptoms and improve quality of life in patients with advanced disease.

How to Use: Epithra is administered by healthcare professionals as an intravenous infusion over a specified period, typically ranging from 15 minutes to several hours, depending on the dosage and treatment regimen. The dosage and duration of treatment are determined by the treating oncologist based on factors such as the type and stage of cancer, the patient’s overall health, and treatment response.

Dosage: The recommended dosage of Epithra varies depending on the specific indication, patient characteristics, and treatment protocol. Healthcare providers calculate the appropriate dosage based on factors such as body surface area, renal function, and previous chemotherapy exposure. Dosage adjustments may be necessary in patients with impaired renal function or other comorbidities.

Efficacy: Clinical studies and extensive clinical experience have demonstrated the efficacy of Epirubicin, the active ingredient in Epithra, in the treatment of breast cancer, ovarian cancer, and soft tissue sarcomas. Its cytotoxic effects on cancer cells and its ability to inhibit tumor growth make it a valuable component of chemotherapy regimens for these malignancies.

Storage: Epithra should be stored according to the manufacturer’s instructions, typically at controlled room temperature, away from moisture, heat, and direct sunlight. The medication should be kept in its original packaging and protected from freezing or extreme temperatures. Unused vials of Epithra should be disposed of properly according to local regulations.

Side Effects: Common side effects of Epithra may include nausea, vomiting, alopecia (hair loss), myelosuppression (decreased blood cell counts), and mucositis (inflammation of the mucous membranes). Less common but more severe side effects may include cardiotoxicity, extravasation injury, and secondary malignancies. Patients should be monitored regularly for adverse effects, and any concerning symptoms should be reported to the healthcare provider promptly.

Precautions: Certain precautions should be observed when using Epithra:

• Cardiac Function: Epithra may cause cardiotoxicity, particularly at high doses or in patients with pre-existing heart disease. Cardiac function should be monitored regularly during treatment, and dosage adjustments may be necessary in patients with cardiac risk factors.
• Extravasation Risk: Epithra is a vesicant that can cause tissue necrosis if it leaks into the surrounding tissues during administration. Healthcare providers should ensure proper venous access and monitor the infusion site closely to prevent extravasation injury.
• Pregnancy and Lactation: Epithra may cause fetal harm if used during pregnancy, so it should be avoided in pregnant women or women planning to become pregnant. Breastfeeding should be discontinued during Epithra therapy.

In summary, Epithra by Glenmark (Onkos) Pharmaceuticals Ltd. offers a potent and effective treatment option for patients with breast cancer, ovarian cancer, and soft tissue sarcomas. With its well-established efficacy, flexible administration, and standardized dosing, Epithra plays a crucial role in the management of these malignancies, helping to improve patient outcomes and quality of life.